What 5‑HT2A antagonists are appropriate for a premenopausal woman with acquired generalized hypoactive sexual desire disorder, and what are their dosing and safety considerations?

Flibanserin for Premenopausal Hypoactive Sexual Desire Disorder

For a premenopausal woman with acquired, generalized hypoactive sexual desire disorder (HSDD), flibanserin 100 mg once daily at bedtime is the appropriate 5-HT2A antagonist treatment option. 1

Mechanism and Indication

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist FDA-approved specifically for acquired, generalized HSDD in premenopausal women. 2 This dual mechanism targets central nervous system pathways involved in sexual desire regulation.

Dosing

• Standard dose: 100 mg once daily at bedtime (qhs)
• Duration: Daily continuous use is required; this is not an on-demand medication
• Timing: Must be taken at bedtime to minimize side effects, particularly dizziness and somnolence

Efficacy Evidence

The strongest evidence comes from pooled analysis of three pivotal 24-week trials (VIOLET, DAISY, BEGONIA) involving 2,465 premenopausal women. 2 Compared to placebo, flibanserin demonstrated:

• Satisfying sexual events: Increased by 2.1 vs 1.2 with placebo over 28 days (p<0.0001)
• Sexual desire (FSFI desire domain): Improved by 0.9 vs 0.6 with placebo (p<0.0001)
• Sexual distress (FSDS-R-13): Reduced by -0.9 vs -0.6 with placebo (p<0.0001)

Individual pivotal trials confirm these findings, with the BEGONIA trial showing increases in satisfying sexual events of 2.5 vs 1.5 with placebo. 3

Safety Profile and Common Pitfalls

Most frequent adverse events (occurring in ≥10% of patients):

• Dizziness
• Somnolence
• Nausea
• Fatigue

1, 2

Critical safety considerations:

• Discontinuation rates due to adverse events: 9.6% with flibanserin vs 3.7% with placebo 3
• Bedtime dosing is essential to minimize dizziness and somnolence during waking hours
• The medication requires daily use; effects are not immediate and build over weeks of treatment
• No withdrawal reactions observed upon discontinuation 4

Patient Selection Criteria

Appropriate candidates are premenopausal women with:

• Acquired (not lifelong) HSDD
• Generalized (not situational) low desire
• Marked distress or interpersonal difficulty related to low desire
• Mean duration of HSDD in trials was approximately 56.5 months 2

Clinical Context and Guideline Support

The 2016 NCCN Survivorship Guidelines specifically recommend discussing flibanserin for "low or lack of desire, libido, intimacy" in females. 1 While these guidelines focus on cancer survivors, flibanserin is not contraindicated in breast cancer patients, though data in this specific population are limited.

Setting Expectations

Counsel patients that:

• This is a daily medication, not taken on-demand before sexual activity
• Improvements occur gradually over the 24-week treatment period
• Side effects are most prominent early in treatment and often diminish with continued use
• Partner/spouse support enhances therapeutic success 1
• The approval remains somewhat controversial given modest effect sizes, requiring realistic expectation-setting 1

Alternative Considerations

While the NCCN guidelines also mention androgens (testosterone) as a discussion option for low desire 1, current evidence primarily supports testosterone use in postmenopausal women with HSDD, not premenopausal women. 5, 6 Therefore, flibanserin remains the evidence-based pharmacologic choice for premenopausal HSDD.